Withings has unveiled a second-generation Body Scan smart scale at CES 2026, expanding its range of health measurements from 40 to 60 biomarkers. The device is designed to bring advanced health tracking features typically found in clinical settings into the home.
The original Body Scan, launched in 2023, already included a six-lead ECG, segmented body composition analysis and nerve health monitoring. The updated model builds on this with new tests aimed at cardiovascular and metabolic health.
The headline addition is Impedance Cardiography (ICG), which assesses how effectively the heart pumps blood to the body’s organs. Another new feature, Bioimpedance Spectroscopy (BIS), uses a low-level electrical current to evaluate total body water. Withings says this data can be used to estimate cellular age, active cell mass and metabolic efficiency.
All measurements are processed through Withings’ “clinically validated” AI system, which generates personalized insights such as estimated risk of hypertension and issues with glycemic regulation. The app also provides an overview of a user’s projected health trajectory and offers recommendations intended to improve long-term healthspan.
The Body Scan 2 features a notable hardware change: The retractable handle that houses the ECG sensors now includes the device’s display. This moves the readout closer to eye level while a user is standing on the scale, although it also concentrates more components into the handle and its connecting cable.
Withings plans to launch the Body Scan 2 in the second quarter of 2026, pending FDA clearance. The scale is expected to retail for $599.95 in the US, €499.95 in Europe and £449.95 in the UK.
CES 2026 runs from January 4 to January 9 in Las Vegas, where companies across the consumer electronics industry are showcasing new products and prototypes.